Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 218
- Registration Number
- NCT05921305
- Locations
- 🇨🇳
Nanfang Hospital, Nanfang Medical University, Guangzhou, Guangdong, China
🇨🇳Peking University Institute of Hematology,, Beijing, Beijing, China
Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT05918718
- Locations
- 🇮🇷
Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05896007
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Tanja Andrea Gruber
- Target Recruit Count
- 90
- Registration Number
- NCT05848687
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- King's College London
- Target Recruit Count
- 90
- Registration Number
- NCT05790330
- Locations
- 🇬🇧
Unit for Paediatric and Population-based Dermatology Research, London, United Kingdom
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Conditions
- Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Calaspargase PegolProcedure: EchocardiographyDrug: Fludarabine PhosphateDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PrednisoloneDrug: PrednisoneDrug: RevumenibDrug: Vincristine Sulfate
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT05761171
- Locations
- 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Tong Chen, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05698147
- Locations
- 🇨🇳
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital Of Fujian Medical University, Fuzhou, Fujian, China
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1122
- Registration Number
- NCT05691478
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
Roflumilast Versus Methotrexate in Psoriasis
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 30
- Registration Number
- NCT05684744
- Locations
- 🇪🇬
Cairo University, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.